2024
An update to the American Radium Society’s appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors
Tom M, Nagpal S, Palmer J, Breen W, Pollom E, Lehrer E, McGranahan T, Shiue K, Chundury A, McClelland Iii S, Saeed H, Chang E, Chiang V, Wang T, Knisely J, Chao S, Milano M. An update to the American Radium Society’s appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors. Radiotherapy And Oncology 2024, 202: 110640. PMID: 39557126, DOI: 10.1016/j.radonc.2024.110640.Peer-Reviewed Original Research
2022
Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas
Tom MC, Milano MT, Chao ST, Soltys SG, Knisely JPS, Sahgal A, Nagpal S, Lo SS, Jabbari S, Wang TJC, Ahluwalia MS, Simonson M, Palmer JD, Gephart MH, Halasz LM, Garg AK, Chiang VLS, Chang EL. Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas. Radiotherapy And Oncology 2022, 170: 79-88. PMID: 35367527, DOI: 10.1016/j.radonc.2022.03.018.Peer-Reviewed Original ResearchConceptsLow-grade gliomasAppropriate use criteriaGrade 2 gliomasGrade 3 gliomasPostoperative managementGrade gliomasIDH-mutant oligodendrogliomasPostoperative therapyRadiotherapy doseAmerican Radium Society Appropriate Use CriteriaGrade 2Gross total surgical resectionImmediate adjuvant therapyHigh-risk featuresType of chemotherapyLow-risk featuresAppropriate treatment optionsIDH-mutant astrocytomasAdjuvant therapyModality therapySurgical resectionConsensus guidelinesTreatment optionsClose surveillanceConsensus recommendations
2020
Executive summary from American Radium Society’s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases
Milano MT, Chiang VLS, Soltys SG, Wang TJC, Lo SS, Brackett A, Nagpal S, Chao S, Garg AK, Jabbari S, Halasz LM, Gephart MH, Knisely JPS, Sahgal A, Chang EL. Executive summary from American Radium Society’s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases. Neuro-Oncology 2020, 22: 1728-1741. PMID: 32780818, PMCID: PMC7746939, DOI: 10.1093/neuonc/noaa192.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyAsymptomatic brain metastasesGood performance statusBrain metastasesMultiple brain metastasesAppropriate use criteriaStereotactic radiosurgeryPerformance statusTreatment optionsAmerican Radium Society Appropriate Use CriteriaHippocampal Sparing-Whole Brain RadiotherapySystematic reviewConventional whole brain radiotherapySingle-fraction stereotactic radiosurgeryProgressive extracranial diseasePoor performance statusAppropriate treatment optionsQuality of evidenceBrainstem metastasesExtracranial diseaseConsensus guidelinesOptimal treatmentSystemic optionsNeurocognitive outcomesPatients